Skip to content
TrialScanner

NCT05812027

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

No phase registeredActive, not recruitingTCRXLead

Registry record

Lead sponsor
TScan Therapeutics, Inc.
Conditions
Head and Neck Cancer; Cervical Cancer; Non Small Cell Lung Cancer; HPV16 Related Cancers; Sarcoma
Primary completion
Jan 1, 2026Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT05812027 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05812027: A Screening Study to Collect... | TrialScanner